Digital Trust & Transparency
Invest in companies poised to benefit as the tech industry faces stricter data privacy enforcement. Following Google's landmark lawsuit, these securities represent businesses providing essential digital security, privacy solutions, and transparent data handling technologies.
Your Basket's Financial Footprint
Summary and investor takeaways for the Digital Trust & Transparency basket based on market capitalisation breakdown.
- Large-cap dominance generally implies lower volatility and performance that tracks broader market moves.
- Suitable as a core holding in diversified portfolios, not a speculative allocation.
- Expect steady, long-term value rather than rapid, short-term gains; growth likely gradual.
CYBR: $25.55B
CRWD: $126.47B
PANW: $145.12B
- Other
About This Group of Stocks
Our Expert Thinking
This collection focuses on companies that address the growing need for digital trust following Google's $314 million penalty for improper data collection. As legal precedents shift toward stricter data privacy enforcement, these companies offer solutions to help businesses avoid similar liability and adapt to a changing regulatory landscape.
What You Need to Know
Companies in this group range from established cybersecurity providers to specialized firms offering privileged access management, zero-trust architecture, and identity protection. Their common thread is providing technologies that enable transparent, compliant data handling—a growing priority as consumers and regulators demand greater control over personal information.
Why These Stocks
These companies were specifically selected because their products and services directly address the vulnerabilities highlighted by the Google verdict. As organizations increase spending on security infrastructure to avoid financial and regulatory risks, these firms are strategically positioned to benefit from this long-term structural trend toward enhanced data governance.
Why You'll Want to Watch These Stocks
The $314 Million Wake-Up Call
Google's landmark penalty signals a new era of enforcement that could reshape how businesses handle data. Companies offering privacy solutions are now at the forefront of a potentially massive market shift.
Corporate Spending Surge
To avoid similar penalties, businesses are ramping up investment in security and compliance technologies. This creates a significant growth opportunity for companies in this group as demand intensifies.
A Long-Term Digital Revolution
Data privacy isn't just a passing concern—it's becoming fundamental to business operations. These stocks represent companies building the infrastructure for a more secure and transparent digital future.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Global Infrastructure Partners: UAE Exposure Risks
The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.
UAE Infrastructure Global Suppliers Breakdown
As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.